EUVIMEDEUVIMED entdecken
Crossref

First Experience With Amulet in the United States

Mohamad Alkhouli, James V Freeman, Christopher R Ellis, Atman P Shah, Hemal Gada, Megan Coylewright, Monica Lo, Akash Makkar, Himanshu Agarwal, Dhanunjaya Lakkireddy

JACC: Cardiovascular Interventions · 2024-02 · 17 (3) · 422-434

DOI: 10.1016/j.jcin.2023.11.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2024-02. Verfasst von Mohamad Alkhouli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Alkhouli.Mohamad@mayo.edu. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Food and Drug Administration approved the Amulet occluder (Abbott) after demonstrating safety and effectiveness in the Amulet IDE (AMPLATZER Amulet LAA Occluder) trial. OBJECTIVES: The aim of the EMERGE Left Atrial Appendage study is to evaluate early postapproval outcomes of the Amulet occluder in the United States using data from the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry. METHODS: Patients with a commercial Amulet occluder implant attempt between Food and Drug Administration approval (August 14, 2021) and December 31, 2022, were included. The safety composite endpoint included all-cause death, ischemic stroke, systemic embolism, or device/procedure-related events requiring open cardiac surgery or endovascular intervention between device implantation and 7 days or hospital discharge (whichever is later). Major adverse events through 45 days were also reported and stratified by operator experience (early [

Schlagwörter

Stichwörter der Autor:innen

AmuletLAAO Registryatrial fibrillationleft atrial appendagestroke

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Alkhouli.Mohamad@mayo.edu.
  • Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Vanderbilt Heart Institute, Nashville, Tennessee, USA.
  • The University of Chicago, Chicago, Illinois, USA.
  • University of Pittsburgh Medical Center, Wormleysburg, Pennsylvania, USA.
  • Erlanger and University of Tennessee Health Science Center, College of Medicine, Chattanooga, Tennessee.

Förderung

  • Abbott Laboratories

Zitieren

APA

Alkhouli, M., Freeman, J. V., Ellis, C. R., Shah, A. P., Gada, H., Coylewright, M., Lo, M., Makkar, A., Agarwal, H., & Lakkireddy, D. (2024). First Experience With Amulet in the United States. JACC: Cardiovascular Interventions, 17(3), 422-434. https://doi.org/10.1016/j.jcin.2023.11.027

Vancouver

Alkhouli M, Freeman JV, Ellis CR, Shah AP, Gada H, Coylewright M, et al. First Experience With Amulet in the United States. JACC: Cardiovascular Interventions. 2024;17(3):422-434. doi:10.1016/j.jcin.2023.11.027

BibTeX
@article{Alkhouli2024,
  author = {Alkhouli, Mohamad and Freeman, James V and Ellis, Christopher R and Shah, Atman P and Gada, Hemal and Coylewright, Megan and Lo, Monica and Makkar, Akash and Agarwal, Himanshu and Lakkireddy, Dhanunjaya},
  title = {First Experience With Amulet in the United States},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  volume = {17},
  number = {3},
  pages = {422--434},
  doi = {10.1016/j.jcin.2023.11.027}
}
Kostenlos starten →